Literature DB >> 15193260

Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.

Ratna K Vadlamudi1, Rozita Bagheri-Yarmand, Zhibo Yang, Seetharaman Balasenthil, Diep Nguyen, Aysegul A Sahin, Petra den Hollander, Rakesh Kumar.   

Abstract

We identified dynein light chain 1 (DLC1) as a physiologic substrate of p21-activated kinase 1 (Pak1). Pak1-DLC1 interaction plays an essential role in cell survival, which depends on Pak1's phosphorylation of DLC1 on Ser88. Pak1 associates with the complex of DLC1 and BimL, a proapoptotic BH3-only protein, and phosphorylates both proteins. Phosphorylation of BimL by Pak1 prevents it from interacting with and inactivation of Bcl-2, an antiapoptotic protein. Overexpression of DLC1 but not DLC1-Ser88Ala mutant promotes cancerous properties of breast cancer cells. DLC1 protein level is elevated in more than 90% of human breast tumors. The regulation of cell survival functions by Pak1-DLC1 interaction represents a novel mechanism by which a signaling kinase might regulate the cancerous phenotypes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193260     DOI: 10.1016/j.ccr.2004.05.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  77 in total

1.  The p21-activated kinase (PAK1) is involved in diet-induced beta cell mass expansion and survival in mice and human islets.

Authors:  Miwon Ahn; Stephanie M Yoder; Zhanxiang Wang; Eunjin Oh; Latha Ramalingam; Ragadeepthi Tunduguru; Debbie C Thurmond
Journal:  Diabetologia       Date:  2016-07-09       Impact factor: 10.122

Review 2.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

3.  Significance of ER-Src axis in hormonal therapy resistance.

Authors:  Sreeram Vallabhaneni; Binoj C Nair; Valerie Cortez; Rambabu Challa; Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2010-12-24       Impact factor: 4.872

4.  Functional regulation of oestrogen receptor pathway by the dynein light chain 1.

Authors:  Suresh K Rayala; Petra den Hollander; Seetharaman Balasenthil; Zhibo Yang; Russell R Broaddus; Rakesh Kumar
Journal:  EMBO Rep       Date:  2005-06       Impact factor: 8.807

5.  pH driven conformational dynamics and dimer-to-monomer transition in DLC8.

Authors:  P M Krishna Mohan; Maneesha Barve; Amarnath Chatterjee; Ramakrishna V Hosur
Journal:  Protein Sci       Date:  2005-12-29       Impact factor: 6.725

Review 6.  NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.

Authors:  Takuro Nakamura
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

7.  Evaluation of an LC8-binding peptide for the attachment of artificial cargo to dynein.

Authors:  Jamie M Bergen; Suzie H Pun
Journal:  Mol Pharm       Date:  2007 Jan-Feb       Impact factor: 4.939

8.  Structural and thermodynamic characterization of a cytoplasmic dynein light chain-intermediate chain complex.

Authors:  John C Williams; Petra L Roulhac; Anindya G Roy; Richard B Vallee; Michael C Fitzgerald; Wayne A Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-05       Impact factor: 11.205

Review 9.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

10.  Resonance Assignments and Secondary Structure Analysis of Dynein Light Chain 8 by Magic Angle Spinning NMR Spectroscopy.

Authors:  Shangjin Sun; Andrew H Butterworth; Sivakumar Paramasivam; Si Yan; Christine M Lightcap; John C Williams; Tatyana Polenova
Journal:  Can J Chem       Date:  2011-08-04       Impact factor: 1.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.